ALK and non-small cell lung carcinoma: Ceritinib and brigatinib are next-generation ALK inhibitors approved for the treatment of patients with ALK-positive NSCLC whose disease has progressed on or who are intolerant to crizotinib (Genentech USA, Inc, 2015; Novartis Pharmaceuticals Corporation, 2014).